Division of Cardiothoracic Surgery, Clinical Research Unit, Emory University School of Medicine, Atlanta, Georgia.
Division of Cardiothoracic Surgery, Clinical Research Unit, Emory University School of Medicine, Atlanta, Georgia.
Ann Thorac Surg. 2014 Feb;97(2):484-90. doi: 10.1016/j.athoracsur.2013.08.041. Epub 2013 Oct 17.
With hybrid coronary revascularization (HCR), minimally invasive left internal mammary artery (LIMA) to left anterior descending coronary artery (LAD) grafting is combined with percutaneous coronary intervention (PCI) of non-LAD vessels. The purpose of this study was to examine the short-term clinical and angiographic results in one of the largest HCR series to date.
From 2003 to 2012, 300 consecutive patients (aged 64±12 years, female 31.7%, predicted risk of mortality 1.6%±2.1%) underwent HCR on an intent-to-treat basis at a single institution. After robotic or thoracoscopic LIMA harvest, off-pump LIMA to LAD grafting was performed through a 3- to 4-cm sternal-sparing, non-rib-spreading thoracotomy. PCI was utilized to treat non-LAD lesions either before, after, or concomitant with the surgical procedure.
Of the 300 patients undergoing HCR on an intent-to-treat basis, HCR was performed with surgery first in 192 patients (64.0%), PCI first in 56 (18.7%), and as a concomitant procedure in 21 (7.0%). Of the 31 patients (10.1%) who did not undergo HCR, 24 patients (8.0%) did not have PCI and thus were incompletely revascularized. For all patients, 30-day mortality, stroke, and nonfatal myocardial infarction occurred in 4 (1.3%), 3 (1.0%), and 4 (1.3%), respectively. Angiographic LIMA evaluation was performed in 248 patients and revealed a FitzGibbon A LIMA patency rate of 97.6% (242 of 248 patients). Repeat revascularization was required in 13 of 300 patients (4.3%).
Hybrid coronary revascularization represents an alternative approach for patients with multivessel coronary disease with excellent short-term outcomes. It provides a minimally invasive alternative to traditional coronary artery bypass graft surgery and may prove more durable than multivessel PCI.
杂交冠状动脉血运重建(HCR)将微创左内乳动脉(LIMA)到左前降支冠状动脉(LAD)搭桥与非 LAD 血管的经皮冠状动脉介入治疗(PCI)相结合。本研究的目的是检查迄今为止最大的 HCR 系列之一的短期临床和血管造影结果。
2003 年至 2012 年,在一家单中心机构,300 例连续患者(年龄 64±12 岁,女性 31.7%,预测死亡率 1.6%±2.1%)进行了意向治疗的 HCR。在机器人或胸腔镜下完成 LIMA 采集后,通过 3 至 4cm 的胸骨保留、非肋骨撑开的开胸术进行非体外循环 LIMA 到 LAD 搭桥。PCI 用于治疗非 LAD 病变,无论是在手术前、后还是同时进行。
在 300 例接受意向治疗的 HCR 的患者中,192 例(64.0%)先进行手术,56 例(18.7%)先进行 PCI,21 例(7.0%)同时进行手术。在 31 例(10.1%)未行 HCR 的患者中,24 例(8.0%)未行 PCI,因此未完全血运重建。对于所有患者,30 天死亡率、卒中和非致命性心肌梗死分别为 4 例(1.3%)、3 例(1.0%)和 4 例(1.3%)。对 248 例患者进行了血管造影 LIMA 评估,显示 FitzGibbon A LIMA 通畅率为 97.6%(242 例中有 248 例)。300 例患者中有 13 例(4.3%)需要再次血运重建。
杂交冠状动脉血运重建为多支血管病变患者提供了一种替代方法,具有极好的短期疗效。它为传统冠状动脉旁路移植术提供了一种微创替代方法,并且可能比多支血管 PCI 更持久。